Data Coordination Center for PDX Net
PDX Net 数据协调中心
基本信息
- 批准号:10261367
- 负责人:
- 金额:$ 89.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-25 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntineoplastic AgentsBenchmarkingBioinformaticsBiological ModelsBiomedical ResearchCancer BiologyCancer PatientClinical TrialsClinical Trials DesignCloud ComputingCollaborationsCommunitiesComputer softwareConsensusCoordination and CollaborationCredentialingDataData AnalysesData CommonsData Coordinating CenterData DiscoveryData SetData Storage and RetrievalDatabasesDevelopmentDrug resistanceEngineeringEnvironmentExperimental DesignsGenomicsGoalsIndividualLaboratoriesLeadershipMalignant NeoplasmsMethodsModelingMolecularNational Cancer InstituteOntologyPatientsPerformancePharmaceutical PreparationsPhenotypePilot ProjectsPrecision therapeuticsPublic HealthRecording of previous eventsReproducibilityResearchResearch PersonnelResource SharingResourcesRiskSecureSpecimenStandardizationSystemTechnologyThe Jackson LaboratoryTraining ActivityUnited States National Institutes of HealthWorkXenograft procedureanticancer researchcancer genomicscancer therapyclinical practicecloud basedcohesioncomputer infrastructurecostdata miningdata resourcedata sharingdata standardsdesigndrug efficacyexperiencegenomics cloudimprovedinnovationlarge datasetslarge scale dataleadership developmentmeetingsoutreachpatient derived xenograft modelpre-clinicalprecision oncologyrepositoryresponsesymposiumsynergismtool
项目摘要
PROJECT SUMMARY
Patient-derived xenografts (PDXs) are a powerful model system for assessing drug efficacy of anti-cancer
agents and understanding molecular mechanisms of drug resistance. However, results from individual
research groups have been difficult to validate due to the lack of standardized PDX procedures, lack of scale
for adequately powered PDX studies and the inability to efficiently share PDX specimens. A key contributor to
this challenge is the lack of well-managed resources for community sharing and large-scale analysis of
integrated, standardized datasets from PDX models. The JAX-Seven Bridges PDX Data Commons and
Coordination Center (PDCCC) seeks to address this challenge and unite the efforts of the component data-
generating (PDX Development and Trial Centers/PDTCs) and PDX model sharing (NCI’s Patient-Derived
Model Repository/PDMR) parts of the PDX Development and Trials Centers Research Network (PDXNet) into
a cohesive, trans-Network whole. Using innovative cloud computing and bioinformatic approaches, our
PDCCC will provide administrative and computational infrastructure for PDXNet to enable PDX method
standardization, model sharing, data sharing, and massive-scale data analysis. We will build a data storage,
sharing, and analysis platform that harmonizes PDXNet data with other large datasets and analysis workflows
available in the NCI Cancer Genomics Cloud. Simultaneously, we will administer planning meetings, training
activities, and research pilots to build synergies within the PDXNet, enhancing the ability of the PDXNet to
develop clinical trials from PDX studies. Our Specific Aims are to 1) establish a leadership and
administration unit to manage and coordinate activities within PDXNet, including annual meetings,
regular conference calls, training activities, trans-Network pilot projects, and outreach; 2) develop a cloud-
integrated PDXnet Data Commons that integrates PDXNet data with the existing cloud-based data analysis
platform - the Seven Bridges Cancer Genomics Cloud (SB-CGC); and 3) build analysis workflows and data
sharing practices to optimize PDXNet research and enable PDXNet data to facilitate clinical trial design. To
accomplish these Aims we have assembled a team with unique expertise in PDXs, cancer treatment, genomic
analysis, data coordination, and project management from The Jackson Laboratory and Seven Bridges. Our
combined institutional strengths include a history of leadership in (and commitment) to PDX, data resource,
analytic and consensus standards development and application; practical expertise in PDX model sharing and
collaborative community efforts; a broad array of statistical, bioinformatic, and software-related PDX resources;
leadership expertise in large-scale, cloud-based biomedical data projects, notably the SB-CGC; and deep
experience in high-performance database engineering and development. Our goal is to build an innovative,
systematically organized PDCCC that will advance the efforts of PDXNet to improve the validity—and expand
use—of the PDX system as a preclinical platform for precision oncology.
项目摘要
患者来源的异种移植物(PDX)是用于评估抗癌药物疗效的强大模型系统。
药物和了解耐药性的分子机制。然而,个人的结果
由于缺乏标准化的PDX程序,缺乏规模,
充分把握度的PDX研究和无法有效共享PDX标本。的主要贡献者
这一挑战是缺乏管理良好的资源,用于社区共享和大规模分析,
PDX模型的集成标准化数据集。JAX-Seven Bridges PDX Data Commons和
协调中心(PDCCC)旨在应对这一挑战,并联合各组成部分的数据-
生成(PDX开发和试验中心/PDTC)和PDX模型共享(NCI的患者衍生
PDX开发和试验中心研究网络(PDXNet)的模型库/PDMR)部分,
一个有凝聚力的跨网络整体利用创新的云计算和生物信息学方法,我们的
PDCCC将为PDXNet提供管理和计算基础设施,以实现PDX方法
标准化、模型共享、数据共享和大规模数据分析。我们会建一个数据存储库,
共享和分析平台,使PDXNet数据与其他大型数据集和分析工作流协调一致
在NCI癌症基因组学云。同时,我们将管理规划会议,培训
活动和研究试点,以建立PDXNet内的协同作用,提高PDXNet的能力,
从PDX研究中开发临床试验。我们的具体目标是:(1)建立领导层,
管理和协调PDXNet内的活动,包括年度会议,
定期电话会议、培训活动、跨网络试点项目和外展; 2)开发云-
集成PDXnet Data Commons,将PDXNet数据与现有基于云的数据分析集成
平台-七桥癌症基因组学云(SB-CGC);以及3)构建分析工作流程和数据
分享实践以优化PDXNet研究,并使PDXNet数据能够促进临床试验设计。到
为了实现这些目标,我们组建了一支在PDX、癌症治疗、基因组学和生物医学领域拥有独特专长的团队。
来自杰克逊实验室和七桥的分析、数据协调和项目管理。我们
综合机构优势包括在PDX,数据资源,
分析和共识标准的开发和应用; PDX模型共享方面的实用专业知识,
协作社区的努力;广泛的统计,生物信息学和软件相关的PDX资源;
在大规模、基于云的生物医学数据项目(特别是SB-CGC)方面的领导专业知识;
高性能数据库工程和开发经验。我们的目标是建立一个创新的,
系统地组织PDCCC,这将推动PDXNet的努力,以提高有效性,并扩大
使用PDX系统作为精确肿瘤学的临床前平台。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey Hsu-Min Chuang其他文献
Jeffrey Hsu-Min Chuang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey Hsu-Min Chuang', 18)}}的其他基金
Summer Undergraduate Research Fellowship in the Molecular Biology and Genomics of Human Cancer
人类癌症分子生物学和基因组学夏季本科生研究奖学金
- 批准号:
9966926 - 财政年份:2019
- 资助金额:
$ 89.35万 - 项目类别:
Summer Undergraduate Research Fellowship in the Molecular Biology and Genomics of Human Cancer
人类癌症分子生物学和基因组学夏季本科生研究奖学金
- 批准号:
9792486 - 财政年份:2019
- 资助金额:
$ 89.35万 - 项目类别:
Summer Undergraduate Research Fellowship in the Molecular Biology and Genomics of Human Cancer
人类癌症分子生物学和基因组学夏季本科生研究奖学金
- 批准号:
10681245 - 财政年份:2019
- 资助金额:
$ 89.35万 - 项目类别:
Quantitative Computational Methods to Accurately Measure Tumor Heterogeneity in Solid Tumors to Inform Development of Evolution-based Treatment Strategies
准确测量实体瘤中肿瘤异质性的定量计算方法,为基于进化的治疗策略的开发提供信息
- 批准号:
9920135 - 财政年份:2018
- 资助金额:
$ 89.35万 - 项目类别:
Quantitative Computational Methods to Accurately Measure Tumor Heterogeneity in Solid Tumors to Inform Development of Evolution-based Treatment Strategies
准确测量实体瘤中肿瘤异质性的定量计算方法,为基于进化的治疗策略的开发提供信息
- 批准号:
10172870 - 财政年份:2018
- 资助金额:
$ 89.35万 - 项目类别:
Quantitative Computational Methods to Accurately Measure Tumor Heterogeneity in Solid Tumors to Inform Development of Evolution-based Treatment Strategies
准确测量实体瘤中肿瘤异质性的定量计算方法,为基于进化的治疗策略的开发提供信息
- 批准号:
10416009 - 财政年份:2018
- 资助金额:
$ 89.35万 - 项目类别:
PDXNet Data Commons and Coordinating Center
PDXNet 数据共享和协调中心
- 批准号:
10732421 - 财政年份:2017
- 资助金额:
$ 89.35万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 89.35万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 89.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 89.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 89.35万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 89.35万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 89.35万 - 项目类别: